<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990791</url>
  </required_header>
  <id_info>
    <org_study_id>STH20412</org_study_id>
    <nct_id>NCT04990791</nct_id>
  </id_info>
  <brief_title>WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?</brief_title>
  <acronym>WILLOW CCS</acronym>
  <official_title>Characterisation of a Novel Regimen of Very Low-dose Aspirin Combined With Rivaroxaban in Patients With Chronic Coronary Syndromes: WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a pharmacodynamic study to determine the effect of a novel regimen of aspirin 20&#xD;
      mg BD plus rivaroxaban 2.5 mg BD on haemostasis, fibrin clot dynamics, inflammatory markers,&#xD;
      platelet function and arachidonic acid metabolites when compared to standard regimens of&#xD;
      aspirin 75 mg OD and aspirin 75 mg OD plus rivaroxaban 2.5 mg BD.&#xD;
&#xD;
      In a randomised open-label three-period crossover design, patient participants receiving&#xD;
      aspirin 75 mg OD for secondary prevention of IHD will be randomised 1:1 to receive one of two&#xD;
      sequences of aspirin: aspirin 75 mg OD, then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD,&#xD;
      then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD; or aspirin 75 mg OD, then aspirin 75 mg OD&#xD;
      plus rivaroxaban 2.5 mg BD, then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD.&#xD;
&#xD;
      At the end of each 14(-2) day medication period, they will attend a study visit at which&#xD;
      blood and urine samples will be obtained, and bleeding time measured, before and 2 hours&#xD;
      after the last dose of IMP of the treatment period. The samples will be tested for fibrin&#xD;
      clot dynamics; inflammatory markers and cytokines; prostanoids; and platelet function.&#xD;
&#xD;
      Participants will be transitioned back to standard-of-care aspirin 75 mg OD at the end of the&#xD;
      third treatment period and followed up by telephone call 14(-2) days later.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment Potential participants will be identified through review of the records of the&#xD;
      South Yorkshire Cardiothoracic Centre and/or by referral by their clinical team.&#xD;
&#xD;
      Specifically, participants may be approached in the following ways:&#xD;
&#xD;
        1. An invitation letter sent by post in combination with a copy of the participant&#xD;
           information sheet. There will be a reply slip which they can return by post, and there&#xD;
           will be contact details (telephone and email) for the research team to allow them to&#xD;
           respond by these methods too.&#xD;
&#xD;
        2. Directly by telephone. In this case, should they be happy to learn more, they will be&#xD;
           sent a copy of the invitation letter, participant information sheet and reply slip by&#xD;
           post or email, depending on their preference. If they agree to attend for study&#xD;
           screening, they will communicate this to the research team by returning the reply slip&#xD;
           by post or email, or by contacting the research team directly using the contact details&#xD;
           provided to them.&#xD;
&#xD;
        3. Directly in clinics within the Cardiology and Cardiothoracic Surgery Directorate at&#xD;
           Sheffield Teaching Hospitals NHS Foundation Trust, upon referral from their clinical&#xD;
           team. In this case they will be provided with a copy of the participant information&#xD;
           sheet and, if unable to decide whether they wish to attend for screening or not during&#xD;
           the clinic visit, will be signposted to the contact details of the research team to&#xD;
           provide their response.&#xD;
&#xD;
           Potential participants who are interested in taking part in the study will then be&#xD;
           contacted by the research team to book a screening appointment.&#xD;
&#xD;
           Screening&#xD;
&#xD;
           Screening will occur at visit 1. The following study procedures will be performed, after&#xD;
           obtaining written consent for the study:&#xD;
&#xD;
             -  Medical history&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Collection of demographic data&#xD;
&#xD;
             -  Vital signs (pulse, blood pressure and temperature).&#xD;
&#xD;
             -  Height, weight and BMI&#xD;
&#xD;
             -  Recording of any concomitant medication&#xD;
&#xD;
             -  Safety blood tests (13.5 ml blood sample for haematology, clinical chemistry and&#xD;
                coagulation)&#xD;
&#xD;
             -  Urinalysis (dipstick), plus urinary pregnancy test if female and of childbearing&#xD;
                potential. This will also be checked immediately prior to first rivaroxaban&#xD;
                exposure at visit 3.&#xD;
&#xD;
             -  Baseline electrocardiogram&#xD;
&#xD;
           Consent Written, informed consent, using the current version of the approved designated&#xD;
           form for this study, will be obtained prior to any study procedures being carried out.&#xD;
           This will be explained and obtained by a medically-qualified member of the research&#xD;
           team, listed on the delegation log. Participants will have the chance to read the&#xD;
           ICF/PIS for as long as they need, and will be able to ask any questions, prior to&#xD;
           signing. Minors and those judged to be without the mental capacity to provide informed&#xD;
           consent will not be enrolled into the study.&#xD;
&#xD;
           Participants will remain free to withdraw at any time from the trial, without giving&#xD;
           reasons and without prejudicing his/her further treatment, and will be provided with a&#xD;
           contact point where he/she may obtain further information about the trial. Samples&#xD;
           collected up to the point of withdrawal will only be used after withdrawal if the&#xD;
           participant consents for this, otherwise they will be destroyed. However, data collected&#xD;
           up to that point will be used for analysis, and this will be explicitly stated in the&#xD;
           participant information sheet and consent form.&#xD;
&#xD;
           The randomisation scheme&#xD;
&#xD;
           Participants will be randomised to one of the following two treatment sequences, in a&#xD;
           1:1 fashion:&#xD;
&#xD;
           (A) Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD&#xD;
           for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD or (B) Aspirin 75 mg OD&#xD;
           for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then&#xD;
           aspirin 20 mg BD plus rivaroxaban 2.5 mg BD&#xD;
&#xD;
           Baseline data At visit 1&#xD;
&#xD;
             -  Medical history&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Demographic data&#xD;
&#xD;
             -  Vital signs (pulse, blood pressure and temperature)&#xD;
&#xD;
             -  Weight and BMI&#xD;
&#xD;
             -  Concomitant medication&#xD;
&#xD;
             -  Lab safety parameters (full blood count, urea &amp; electrolytes, liver function tests,&#xD;
                clotting screen, dipstick urinalysis, urinary pregnancy test if female and of&#xD;
                childbearing potential)&#xD;
&#xD;
             -  Electrocardiogram findings At visit 2&#xD;
&#xD;
             -  Vital signs: pulse, blood pressure and temperature&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
           Visit 1 - Screening (Day -21 to 0)&#xD;
&#xD;
           Screening of subjects and all study-related procedures will take place in the Sheffield&#xD;
           Clinical Research Facility, a specialist environment for the conduct of clinical&#xD;
           research. The following assessments and procedures will be performed:&#xD;
&#xD;
           - Full informed consent, including completion of the informed consent form&#xD;
&#xD;
             -  Inclusion/exclusion criteria (see section 6)&#xD;
&#xD;
             -  Medical history&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Demographic data&#xD;
&#xD;
             -  Vital signs: pulse, blood pressure and temperature&#xD;
&#xD;
             -  Weight and BMI&#xD;
&#xD;
             -  Concomitant medication&#xD;
&#xD;
             -  Lab safety (13.5 ml blood sample for haematology; clinical chemistry &amp; coagulation;&#xD;
                urinalysis)&#xD;
&#xD;
             -  Electrocardiogram&#xD;
&#xD;
           Visit 2 (Day 0) - Randomisation&#xD;
&#xD;
             -  Vital signs&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Reconfirm eligibility criteria met (by a medically qualified member of the study&#xD;
                team, see section 6) and no withdrawal criteria met (section 7.10)&#xD;
&#xD;
             -  Randomisation&#xD;
&#xD;
             -  Provided with supply of aspirin (aspirin lysine) for periods 1, 2 and 3 (2 boxes of&#xD;
                30 sachets)&#xD;
&#xD;
             -  Dose-preparation training for aspirin (aspirin lysine) 75 mg OD, including supply&#xD;
                of written illustrated instructions&#xD;
&#xD;
             -  Issue with participant information card detailing treatment allocation,&#xD;
                restrictions during the study and contact details for the research team&#xD;
&#xD;
           Period 1: 14 (-2) days - Participants will receive aspirin (aspirin lysine) 75 mg OD,&#xD;
           but should withhold their dose on the morning of visit 3 (during which the dose will be&#xD;
           taken).&#xD;
&#xD;
           Visit 3 - Period 1: Day 14 (-2)&#xD;
&#xD;
             -  Vital signs&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Adverse event recording&#xD;
&#xD;
             -  Concomitant medication recorded&#xD;
&#xD;
             -  Venous blood sample pre- and 2 hours post-dose for fibrin clot dynamics,&#xD;
                inflammatory markers, prostanoids and platelet function&#xD;
&#xD;
             -  Bleeding time pre- and 2 hours post dose&#xD;
&#xD;
             -  Urine sample pre- and 2 hours post-dose for prostanoids&#xD;
&#xD;
             -  IMP compliance check for period 1&#xD;
&#xD;
             -  Dispensing of rivaroxaban 2.5 mg tablets for periods 2 and 3 (total 56 tablets)&#xD;
&#xD;
             -  Urine pregnancy test for women of childbearing potential (must not continue to&#xD;
                period 2 if positive)&#xD;
&#xD;
             -  Dose-preparation training for aspirin (aspirin lysine) 20 mg BD if allocated to&#xD;
                sequence A, including provision of written instructions&#xD;
&#xD;
           Period 2: 14(-2) days&#xD;
&#xD;
           Participants will receive their allocated regimen for period 2 for 14(-2) days:&#xD;
&#xD;
             -  If randomised to sequence A they will receive aspirin (aspirin lysine) 20 mg BD&#xD;
                plus rivaroxaban 2.5 mg BD in period 2.&#xD;
&#xD;
             -  If randomised to sequence B they will receive aspirin (aspirin lysine) 75 mg BD&#xD;
                plus rivaroxaban 2.5 mg BD in period 2.&#xD;
&#xD;
           Participants should withhold their dose on the morning of visit 4 (during which the dose&#xD;
           will be taken).&#xD;
&#xD;
           Visit 4 : 14(-2) days into period 2 - Physical examination&#xD;
&#xD;
             -  Adverse event recording&#xD;
&#xD;
             -  Concomitant medication recorded&#xD;
&#xD;
             -  Venous blood sample pre- and 2 hours post-dose for fibrin clot dynamics,&#xD;
                inflammatory markers, prostanoids and platelet function&#xD;
&#xD;
             -  Bleeding time pre- and 2 hours post dose&#xD;
&#xD;
             -  Urine sample pre- and 2 hours post-dose for prostanoids&#xD;
&#xD;
             -  IMP compliance recorded for period 2&#xD;
&#xD;
             -  Dose-preparation training for aspirin (aspirin lysine) 75 mg OD if allocated to&#xD;
                sequence A or 20 mg BD if sequence B, including provision of written instructions&#xD;
&#xD;
           Period 3: 14(-2) days&#xD;
&#xD;
           Participants will receive their allocated regimen for period 3 for 14(-2) days:&#xD;
&#xD;
             -  If randomised to sequence A they will receive aspirin (aspirin lysine) 75 mg OD&#xD;
                plus rivaroxaban 2.5 mg BD in period 3.&#xD;
&#xD;
             -  If randomised to sequence B they will receive aspirin (aspirin lysine) 20 mg BD&#xD;
                plus rivaroxaban 2.5 mg BD in period 3.&#xD;
&#xD;
           Visit 5 : 14(-2) days into period 3 - Vital signs&#xD;
&#xD;
           - Physical examination&#xD;
&#xD;
           - Adverse event recording&#xD;
&#xD;
           - Concomitant medication recorded&#xD;
&#xD;
           - Venous blood sample pre- and 2 hours post-dose for fibrin clot dynamics, inflammatory&#xD;
           markers, prostanoids and platelet function&#xD;
&#xD;
           - Bleeding time pre- and 2 hours post dose&#xD;
&#xD;
           - Urine sample pre- and 2 hours post-dose for prostanoids&#xD;
&#xD;
           - IMP compliance recorded for period 3&#xD;
&#xD;
             -  Collect and return unused medication to pharmacy&#xD;
&#xD;
             -  Transition to standard of care aspirin 75 mg OD, ensuring participant has a supply&#xD;
                of this&#xD;
&#xD;
           Visit 6 : 14(-2) days after visit 5 (Telephone call) - Telephone follow-up for adverse&#xD;
           events and concomitant medication&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomised controlled open-label crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Time Difference</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>The primary endpoint will be difference in bleeding time, measured at 2 hours post-dose, assessed between aspirin (aspirin lysine) 75 mg once-daily alone vs. aspirin (aspirin lysine) 20 mg twice-daily plus rivaroxaban 2.5 mg twice-daily and aspirin (aspirin lysine) 75 mg once-daily alone vs. aspirin (aspirin lysine) 75 mg once-daily plus rivaroxaban 2.5 mg twice-daily.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding time pre-dose</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in bleeding time measured at pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin clot lag time by fibrin clot turbidimetry</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in fibrin clot lag time at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin clot lysis time by fibrin clot turbidimetry</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in fibrin lysis lag time at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma TNF by enzyme-linked immunosorbent assay (ELISA)/multiplex bead assay (MBA)</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Plasma TNF-α at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IL-6 by ELISA</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Plasma IL-6 at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CRP (Roche Cobas assay)</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Serum CRP at 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte count (and subsets), by automated cell counting</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Leukocyte count at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TXB2 by ELISA</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Serum TXB2 at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PGI-M by ELISA</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Urine PGI-M at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine TxM by ELISA</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the difference in Urine TxM at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation responses to AA, collagen and adenosine diphosphate ADP by light transmittance aggregometry</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>Mean platelet aggregation responses to arachidonic acid (AA), collagen and adenosine diphosphate (ADP), at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final clot turbidity by fibrin clot turbidimetry</measure>
    <time_frame>Until 14 (-2) days after last IMP dose</time_frame>
    <description>A secondary endpoint will be the final clot turbidity at pre-dose and 2 hours post-dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Aspirin 20mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asprin 75mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aspirin 75 mg OD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 75mg</intervention_name>
    <description>Aspirin 75mg OD for 14 days</description>
    <arm_group_label>Aspirin 20mg</arm_group_label>
    <arm_group_label>Asprin 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 20mg</intervention_name>
    <description>Aspirin 20mg BD for 14 days</description>
    <arm_group_label>Aspirin 20mg</arm_group_label>
    <arm_group_label>Asprin 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 mg</intervention_name>
    <description>Rivaroxaban 2.5mg BD</description>
    <arm_group_label>Aspirin 20mg</arm_group_label>
    <arm_group_label>Asprin 75mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Male or female aged greater than 18 years&#xD;
&#xD;
          3. Existing diagnosis of a chronic coronary syndrome:&#xD;
&#xD;
             (i) History of stable angina or (ii) History of an acute coronary syndrome event &gt;1&#xD;
             year ago or (iii) Previous evidence on imaging of either at least one stenosis &gt;50% in&#xD;
             an epicardial coronary artery or a myocardial perfusion defect&#xD;
&#xD;
          4. Receiving single antiplatelet therapy with aspirin 75 mg once daily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of haemorrhagic stroke or lacunar stroke&#xD;
&#xD;
          2. History of ischaemic stroke or transient ischaemic attack in the last year&#xD;
&#xD;
          3. Heart failure associated with NYHA class III or IV symptoms&#xD;
&#xD;
          4. Estimated glomerular filtration rate &lt;15 ml/min&#xD;
&#xD;
          5. Planned procedure for coronary revascularization&#xD;
&#xD;
          6. Any planned surgery or other procedure that may require suspension or discontinuation&#xD;
             of antiplatelet therapy expected to occur within 3 months of randomisation&#xD;
&#xD;
          7. Prior intention by patient or physician to discontinue aspirin within the study period&#xD;
&#xD;
          8. Receiving doses of aspirin other than 75 mg once daily&#xD;
&#xD;
          9. Treatment or planned treatment with antiplatelet medication apart from aspirin (eg.&#xD;
             clopidogrel, prasugrel, ticagrelor, dipyridamole, ticlopidine)&#xD;
&#xD;
         10. Current use of a loop, thiazide or potassium sparing diuretic (affects prostanoid&#xD;
             assays)&#xD;
&#xD;
         11. Any acute coronary syndrome event, percutaneous coronary intervention or coronary&#xD;
             artery bypass grafting within 1 year prior to randomisation&#xD;
&#xD;
         12. Current or planned use of an oral anticoagulant (e.g. warfarin, dabigatran,&#xD;
             rivaroxaban [including 2.5 mg BD], apixaban, edoxaban) or parenteral anticoagulant&#xD;
             (eg. unfractionated heparin, low molecular weight heparin, bivalirudin)&#xD;
&#xD;
         13. Current or planned use of a GPIIb/IIIa inhibitor (eg. abciximab, tirofiban)&#xD;
&#xD;
         14. Current or planned use of a fibrinolytic agent (eg. tissue plasminogen activator)&#xD;
&#xD;
         15. Requiring or likely to require treatment with a non-steroidal anti-inflammatory drug&#xD;
             (NSAID), including COX2 inhibitors, and including regular or intermittent/as required&#xD;
             use&#xD;
&#xD;
         16. Current or planned use of a strong CYP3A4 inhibitor (eg, ketoconazole, itraconazole,&#xD;
             voriconazole, telithromycin, clarithromycin [but not erythromycin or azithromycin],&#xD;
             nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, cobicistat or&#xD;
             over 1 litre daily of grapefruit juice), strong inducer (e.g. rifampin/rifampicin,&#xD;
             rifabutin, phenytoin, carbamazepine, phenobarbital), a selective serotonin reuptake&#xD;
             inhibitor (SSRI) or selective noradrenergic reuptake inhibitor (SNRI).&#xD;
&#xD;
         17. Clinically significant liver disease, defined as known or suspected diagnosis of&#xD;
             hepatic cirrhosis with current Child Pugh class B or C; or elevation of serum alanine&#xD;
             transferase or aspartate transferase greater than 3 times the upper limit of the&#xD;
             normal range for the processing laboratory.&#xD;
&#xD;
         18. History of alcohol or drug abuse, defined as regular use of an illicit substance for&#xD;
             recreational purposes or regular consumption of greater than 50 units (males) or 35&#xD;
             units (females) of alcohol per week, in the last year&#xD;
&#xD;
         19. Co-morbidity associated with life expectancy less than 1 year&#xD;
&#xD;
         20. Any other condition deemed by the investigator to significantly affect haemostasis,&#xD;
             coagulation, bleeding risk or ability to comply with the study protocol.&#xD;
&#xD;
         21. Females of child-bearing potential unless negative pregnancy test at screening and&#xD;
             willing to use effective contraception (i.e. established use of oral, injected or&#xD;
             implanted hormonal methods of contraception or placement of an intrauterine device&#xD;
             (IUD) or intrauterine system (IUS) or barrier methods of contraception with spermicide&#xD;
             or sole male partner with prior vasectomy and confirmed absence of sperm in ejaculate)&#xD;
             for the duration of treatment with study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Storey</last_name>
      <phone>0114 2159554</phone>
      <phone_ext>59554</phone_ext>
      <email>R.F.Storey@sheffield.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1.</citation>
    <PMID>23996286</PMID>
  </reference>
  <reference>
    <citation>Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4242.</citation>
    <PMID>31504439</PMID>
  </reference>
  <reference>
    <citation>Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.</citation>
    <PMID>28844192</PMID>
  </reference>
  <reference>
    <citation>Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA, Storey RF. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J. 2018 Apr 1;39(13):1078-1085. doi: 10.1093/eurheartj/ehy013.</citation>
    <PMID>29390064</PMID>
  </reference>
  <reference>
    <citation>Königsbrügge O, Weigel G, Quehenberger P, Pabinger I, Ay C. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Clin Exp Med. 2018 Aug;18(3):325-336. doi: 10.1007/s10238-018-0490-9. Epub 2018 Feb 7.</citation>
    <PMID>29417256</PMID>
  </reference>
  <reference>
    <citation>Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G. Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. J Am Coll Cardiol. 2017 Oct 3;70(14):1760-1776. doi: 10.1016/j.jacc.2017.08.037. Review.</citation>
    <PMID>28958334</PMID>
  </reference>
  <reference>
    <citation>Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 May 5;330(18):1287-94. Review.</citation>
    <PMID>8145785</PMID>
  </reference>
  <reference>
    <citation>Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariëns RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009 May;29(5):712-7. doi: 10.1161/ATVBAHA.109.183707. Epub 2009 Mar 12.</citation>
    <PMID>19286636</PMID>
  </reference>
  <reference>
    <citation>Kiers D, van der Heijden WA, van Ede L, Gerretsen J, de Mast Q, van der Ven AJ, El Messaoudi S, Rongen GA, Gomes M, Kox M, Pickkers P, Riksen NP. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost. 2017 Aug 30;117(9):1798-1807. doi: 10.1160/TH16-10-0799. Epub 2017 Jul 6.</citation>
    <PMID>28692111</PMID>
  </reference>
  <reference>
    <citation>Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE, Ecob R, Judge HM, Khan H, West LE, Dockrell DH, Sabroe I, Storey RF. Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2562-70. doi: 10.1161/ATVBAHA.115.306528. Epub 2015 Oct 29.</citation>
    <PMID>26515417</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.</citation>
    <PMID>28845751</PMID>
  </reference>
  <reference>
    <citation>Teng R, Maya J, Butler K. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets. 2013;24(8):615-24. doi: 10.3109/09537104.2012.748185. Epub 2012 Dec 18.</citation>
    <PMID>23249161</PMID>
  </reference>
  <reference>
    <citation>Choi J, Hwang SY, Ahn K. Interplay between RNASEH2 and MOV10 controls LINE-1 retrotransposition. Nucleic Acids Res. 2018 Feb 28;46(4):1912-1926. doi: 10.1093/nar/gkx1312.</citation>
    <PMID>29315404</PMID>
  </reference>
  <reference>
    <citation>Ghys T, Malfait R, VAN den Bossche J. Performance evaluation of the Sysmex XS-1000i automated haematology analyser. Int J Lab Hematol. 2009 Oct;31(5):560-6. doi: 10.1111/j.1751-553X.2008.01081.x. Epub 2009 Jun 18.</citation>
    <PMID>18616754</PMID>
  </reference>
  <reference>
    <citation>Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, Judge HM, Ajjan RA, Rocca B, Storey RF. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets. 2019;30(2):148-157. doi: 10.1080/09537104.2019.1572880. Epub 2019 Feb 13.</citation>
    <PMID>30759035</PMID>
  </reference>
  <reference>
    <citation>Doroszko A, Szahidewicz-Krupska E, Janus A, Jakubowski M, Turek A, Ilnicka P, Szuba A, Mazur G, Derkacz A. Endothelial dysfunction in young healthy men is associated with aspirin resistance. Vascul Pharmacol. 2015 Apr-Jun;67-69:30-7. doi: 10.1016/j.vph.2015.02.001. Epub 2015 Feb 17.</citation>
    <PMID>25697550</PMID>
  </reference>
  <reference>
    <citation>Olson MT, Kickler TS, Lawson JA, McLean RC, Jani J, FitzGerald GA, Rade JJ. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. J Thromb Haemost. 2012 Dec;10(12):2462-9. doi: 10.1111/jth.12026.</citation>
    <PMID>23072449</PMID>
  </reference>
  <reference>
    <citation>Sánchez A, Mirabel JL, Barrenechea E, Eugui J, Puelles A, Castañeda A. Evaluation of an improved immunoturbidimetic assay for serum C-reactive protein on a COBAS INTEGRA 400 Analyzer. Clin Lab. 2002;48(5-6):313-7.</citation>
    <PMID>12071582</PMID>
  </reference>
  <reference>
    <citation>Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985 Oct;69(10):1071-77.</citation>
    <PMID>4042087</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data arising from the trial will be owned by University of Sheffield and will not be disseminated to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

